Logo

Shanghai Taiyin Biotechnology Reports Preclinical Study of Omalizumab Biosimilar KA

Share this

Shanghai Taiyin Biotechnology Reports Preclinical Study of Omalizumab Biosimilar KA

Shots:

  • Preclinical studies of the proposed omalizumab biosimilar KA showed similarities to Xolair in terms of analytical characteristics, in vitro biological activity, pharmacology, and toxicology in animals. Omalizumab is a mAb targeting IgE used to treat mod. to sev. asthma
  • Structure & binding activity were similar to the reference Xolair, no significant differences in pharmacological, PK, and toxicity profiles were observed. The mouse model's findings also revealed that in vivo pharmacologic effects were similar
  • Additionally, KA has similar activity to the omalizumab reference product in cell-free, in vitro, and relevant in vivo preclinical models, and the results demand a clinical analysis of biosimilarity

Ref: Centre for Biosimilars | Image: BMS 

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions